The discovery of mutations in the epidermal growth factor receptor (EGFR) gene allowed for the development of tyrosine kinase inhibitors (TKIs) as first-line treatment for advanced/metastatic non-small-cell lung cancer harboring EGFR mutations. Here, EGFR is linked to non-small cell lung carcinoma.